

FORM PTO-1390 (REV 11-95)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NUMBER <b>3525-95</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/623705</b>
INTERNATIONAL APPLICATION NO. <b>PCT/SE00/01252</b>	INTERNATIONAL FILING DATE <b>15 Jun 2000</b>	PRIORITY DATE CLAIMED <b>16 Jun 1999</b>
TITLE OF INVENTION <b>NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS</b>		
APPLICANT(S) FOR DO/EO/US <b>BJORSNE et al</b>		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This is an express request to **DELAY** national examination procedures (35 U.S.C. 371(f) until the expiration of the applicable time limit set in 35 U.S.C. 371(b) Articles 22 and 39(1).
- ☐ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.

5 A copy of the International Application as filed (35 U.S.C. 371(c)(2)).

- ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
- ☐ has been transmitted by the International Bureau.
- ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).

6 ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).

☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).

- ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
- ☐ have been transmitted by the International Bureau.
- ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
- ☐ have not been made and will not be made.


8 ☐ A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)).

9 ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

10 ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. To 16. Below concern document(s) or information included:**

- ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
- ☒ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
- ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
- ☐ A substitute specification.
- ☐ A change of power of attorney and/or address letter.
- ☐ Other items or information.

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.53(a)) <b>09/623705</b>		INTERNATIONAL APPLICATION NO. <b>PCT/SE00/01252</b>		ATTORNEY'S DOCKET NUMBER <b>3525-95</b>	
17. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b> PTO USE ONLY	
<b>BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5)):</b> -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....\$970.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....\$840.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO .....\$690.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....\$670.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) .....\$96.00  <div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div>				\$	970.00
				\$	0.00
				Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).	
<b>CLAIMS</b>	<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>		
Total Claims	26	-20 =	6	X	\$18.00
Independent Claims	1	-3 =	0	X	\$78.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)				\$260.00	\$ 0.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	<b>1078.00</b>
Reduction by 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 C.F.R. 1.9, 1.27, 1.28).				\$	0.00
<b>SUBTOTAL =</b>				\$	<b>1078.00</b>
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).				\$	0.00
<b>TOTAL NATIONAL FEE =</b>				\$	<b>1078.00</b>
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				\$	40.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1210.00 - Small Entity = \$605.00)				\$	0.00
<b>TOTAL FEES ENCLOSED =</b>				\$	<b>1118.00</b>
				Amount to be:	
				refunded	\$
				Charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1118.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application. <b>NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>  <b>SEND ALL CORRESPONDENCE TO:</b>  NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 <sup>th</sup> Floor Arlington, Virginia 22201 Telephone: (703) 816-4000					
				SIGNATURE	
				<b>Leonard C. Mitchard</b>	
				NAME	
				<b>29,009</b>	September 7, 2000
				REGISTRATION NUMBER	Date

AstraZeneca



08/623705

533 Rec'd PCT/PTO 07 SEP 2000

Applicant: **AstraZeneca AB**  
S-151 85 Södertälje  
Sweden

Title: **NEW BISPIDINE COMPOUNDS USEFUL IN THE**  
**TREATMENT OF CARDIAC ARRHYTHMIAS**

Reference: H 2127-1 WO

Inventors: BJÖRSNE, Magnus  
FRANTSI, Marianne  
HOFFMANN, Kurt-Jürgen  
OHLSSON, Bengt

002000-50222960